NASDAQ:RANI

Rani Therapeutics Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy RANI

*Your capital is at risk

$0.774

-0.0462 (-5.63%)

At Close: Jul 31, 2026

Rani Therapeutics Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -43.34. In total, the insiders bought 19.36M and sold 6.56M RANI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-43.34
● Buy	19.36M shares
● Sell	6.56M shares
75% Buy Activity Moderate Positive Correlation
Buy Signal Low Confidence Jul 17, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -43.34. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Mckinley Kate Chief Business Officer	Officer	325 000 Value: $200.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Imran Talat Chief Executive Officer	CEO / President	1 053 000 Value: $649.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Sanford Svai S Chief Financial Officer	C-Suite Officer	325 000 Value: $200.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Sanford Svai S Chief Financial Officer	C-Suite Officer	325 000 Value: $200.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Imran Talat Chief Executive Officer	CEO / President	1 053 000 Value: $649.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Mckinley Kate Chief Business Officer	Officer	325 000 Value: $200.5K
May 23, 2025 Buy	Stock Option (Right to Buy) A-Award	Hashim Mir Chief Scientific Officer	Officer	325 000 Value: $200.5K
Dec 27, 2024 Sell	Class A Common Stock S-Sale	Imran Talat Chief Executive Officer	CEO / President	8 014 Value: $11.3K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Butel Jean Luc Director	Director	18 875 Value: $178.2K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Butel Jean Luc Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Butel Jean Luc Director	Director	18 875 Value: $53.6K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Ausiello Dennis A Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Ausiello Dennis A Director	Director	15 423 Value: $145.6K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Ausiello Dennis A Director	Director	15 423 Value: $43.8K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Rometty Lisa Ann Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Rometty Lisa Ann Director	Director	17 708 Value: $167.2K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Rometty Lisa Ann Director	Director	17 708 Value: $50.3K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Debuono Laureen Director	Director	18 875 Value: $178.2K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Debuono Laureen Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Debuono Laureen Director	Director	18 875 Value: $53.6K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Farquharson Andrew Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Farquharson Andrew Director	Director	101 276 Value: $287.6K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Imran Mir A Director	Director	101 276 Value: $416.2K
Dec 16, 2024 Sell	Stock Option (Right to Buy) D-Return	Imran Mir A Director	Director	101 276 Value: $287.6K
Dec 16, 2024 Buy	Stock Option (Right to Buy) A-Award	Nanavaty Maulik Director	Director	101 276 Value: $416.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RANI THERAPEUTICS HOLDINGS, INC.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...

Read Full Profile Here